-transparent.png){kind=logo}
[Vogt-Koyanagi-Harada disease associated with interferon-alpha and ribavirin therapy for chronic hepatitis C infection]. 2010
Service B, Institut Hédi Rais d'ophtalmologie, Tunis, Tunisie. chebilahmed@yahoo.fr <chebilahmed@yahoo.fr>
The complex immunological effects of interferon and ribavirin therapy in hepatitis C virus may also exacerbate or trigger the development of autoimmunity. A rare case of Vogt-Koyanagi-Harada disease associated with ribavirin and interferon-alpha treatment for chronic hepatitis C infection is presented. The potential role of interferon and/or ribavirin therapy is discussed. Physicians should be aware of the association between interferon-alpha 2a and ribavirin use for hepatitis C infection and the development of Harada disease. This severe ophthalmological complication requires close follow-up of hepatitis C virus-infected patients on interferon-alpha treatment.
Related Publications
A Chebil, and
F Kort, and
R Bouraoui, and
N Ben Youssef, and
L El Matri
February 2006,
The Journal of infection,
A Chebil, and
F Kort, and
R Bouraoui, and
N Ben Youssef, and
L El Matri
October 2010,
International ophthalmology,
A Chebil, and
F Kort, and
R Bouraoui, and
N Ben Youssef, and
L El Matri
November 2003,
Journal of viral hepatitis,
A Chebil, and
F Kort, and
R Bouraoui, and
N Ben Youssef, and
L El Matri
November 2004,
Journal of gastroenterology,
A Chebil, and
F Kort, and
R Bouraoui, and
N Ben Youssef, and
L El Matri
March 2011,
The Korean journal of hepatology,
A Chebil, and
F Kort, and
R Bouraoui, and
N Ben Youssef, and
L El Matri
January 2011,
Case reports in ophthalmology,
A Chebil, and
F Kort, and
R Bouraoui, and
N Ben Youssef, and
L El Matri
November 2005,
American journal of ophthalmology,
A Chebil, and
F Kort, and
R Bouraoui, and
N Ben Youssef, and
L El Matri
January 2019,
Ocular immunology and inflammation,
A Chebil, and
F Kort, and
R Bouraoui, and
N Ben Youssef, and
L El Matri
January 2019,
Ocular immunology and inflammation,
A Chebil, and
F Kort, and
R Bouraoui, and
N Ben Youssef, and
L El Matri
June 2018,
Internal medicine (Tokyo, Japan),
